<DOC>
	<DOCNO>NCT01855724</DOCNO>
	<brief_summary>The purpose study determine whether gemcitabine pazopanib effective treatment inoperable , locally advanced metastatic biliary tree cancer ( cholangiocarcinoma gallbladder carcinoma ) .</brief_summary>
	<brief_title>Clinical Trial Investigate Efficacy Treatment With Gemcitabine/Pazopanib Patients With Biliary Tree Cancer</brief_title>
	<detailed_description>This open label , uncontrolled , multicenter , phase II study evaluate efficacy safety Gemcitabine/Pazopanib combination 1st line treatment patient unresectable , locally advanced metastatic biliary tree adenocarcinoma . A total 46 patient include study . The patient receive open label Gemcitabine 1000 mg/m2 intravenously day 1 8 Pazopanib 800 mg per o day 1 21 every 21 day . Treatment gemcitabine/pazopanib combination continue disease progression , appearance significant toxicity , completion 8 cycle inform consent withdrawal . Upon completion 8 treatment cycle combination , absence disease progression , administration pazopanib monotherapy maintenance treatment continue disease progression , appearance significant toxicity inform consent withdrawal . Imaging assessment perform every 8 week</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Subjects must provide write informed consent prior performance studyspecific procedures assessment , must willing comply treatment follow . Age ≥18 year Histologically confirm diagnosis inoperable , locally advanced metastatic cholangiocarcinoma ( adenocarcinoma intrahepatic , proximal extrahepatic , distal extrahepatic , gallbladder adenocarcinoma periampullary bile duct adenocarcinoma ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Measurable disease criterion per RECIST v1.1 . No prior chemotherapy treatment target therapy Formalinfixed paraffinembedded tumour whole blood/plasma sample diagnosis/study enrollment biomarker study . Adequate organ system function specify protocol Female patient allow participate provide consent avoid pregnancy throughout course trial 1 month last administration drug , surgically sterilize menopausal . Prior malignancy.Subjects history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma indolent prostate cancer eligible ( even receive antihormonal therapy ) . Central nervous system ( CNS ) metastases baseline , exception subject previouslytreated CNS metastasis asymptomatic requirement steroid enzymeinducing anticonvulsant past 6 month . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal , 28 day prior study treatment initiation . Clinically significant gastrointestinal abnormality may affect absorption investigational product include malabsorption syndrome , major resection stomach Corrected QT interval ( QTc ) &gt; 480 millisecond use Bazett 's formula History myocardial infarction , unstable angina , symptomatic peripheral vascular disease Class II , III IV congestive heart failure , define New York Heart Association ( NYHA ) cardiac angioplasty stenting within past 6 month Newlydiagnosed hypertension history poorly control hypertension [ define systolic blood pressure ( SBP ) ≥140 millimeter mercury ( mmHg ) diastolic blood pressure ( DBP ) ≥90mmHg ] . History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 months.Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible Major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer ( procedure catheter placement consider major ) . Evidence active bleeding bleed diathesis . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel increase risk pulmonary hemorrhage Recent hemoptysis ( ≥ ½ teaspoon red blood within 8 week first dose study drug ) . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . Unable unwilling discontinue use prohibit medication least 14 day five halflives drug ( whichever longer ) prior first dose study drug duration study Radiation therapy , surgery tumor embolization within 14 day prior first dose pazopanib Administration nononcologic investigational study drug within 30 day 5 half life whichever longer prior receive first dose study treatment . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity , except alopecia . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>